Urge Your Elected Officials to Provide Dedicated Funding for SCD Data Collection
As the appropriations process continues in the House of
Representatives and Senate for fiscal year (FY) 2020, ASH is working hard to
expand key sickle cell disease (SCD) programs within the Centers for Disease
Control and Prevention (CDC).
Tell Congress to Support NIH Funding for FY 2020
The Society needs the help of all its members to urge lawmakers to support
the robust, sustained, and predictable funding increases for NIH that are
currently proposed in the House Labor-HHS spending bill. You can help spread
this message by quickly sending an email to your legislators.
Write Your New Jersey Legislators to Support Patients' Access to Care
Legislation has been introduced in the New Jersey Legislature that would ensure that patients have access to the life-saving medication that is prescribed to them by their physicians.
will place maximums on the out-of-pocket (OOP) costs that patients can be required to pay for each prescription medication, regardless of the disease. The legislation caps patient OOP costs for prescription medications within state regulated plans and would dramatically improve affordability for patients without significantly altering the existing insurance marketplace. This bill has already passed the New Jersey Assembly by a vote of 77-1 but must now be considered in the state Senate. Your help is needed to urge your state senator to give S. 1865 a hearing and vote during this legislative session.
Urge Your Senators and Representative to Support the Cancer Drug Coverage Parity Act
Legislation has been reintroduced in the U.S. House of
Representatives and U.S. Senate that would ensure that patients enrolled in
certain federally regulated health plans have access and insurance coverage for
all anti-cancer regimens. The Cancer Drug Coverage Parity Act (S.741
/ H.R.1730) would require any health plan that provides coverage for cancer
chemotherapy treatment to provide coverage for orally administered and
self-injectable anticancer medications at a cost no less favorable than the
cost of IV, port administered, or injected anticancer medications.